Follow
deepak mittal
deepak mittal
Senior Research Officer
Verified email at qimr.edu.au
Title
Cited by
Cited by
Year
New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
D Mittal, MM Gubin, RD Schreiber, MJ Smyth
Current opinion in immunology 27, 16-25, 2014
18002014
Targeting cancer-derived adenosine: new therapeutic approaches
A Young, D Mittal, J Stagg, MJ Smyth
Cancer discovery 4 (8), 879-888, 2014
3092014
Targeted therapies for triple-negative breast cancer: combating a stubborn disease
M Kalimutho, K Parsons, D Mittal, JA López, S Srihari, KK Khanna
Trends in pharmacological sciences 36 (12), 822-846, 2015
3012015
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor
D Mittal, A Young, K Stannard, M Yong, MWL Teng, B Allard, J Stagg, ...
Cancer research 74 (14), 3652-3658, 2014
2672014
Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy
SMJ Blake S, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Roman Aguilera A ...
Cancer Discovery, 2016
2232016
TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells
D Mittal, F Saccheri, E Vénéreau, T Pusterla, ME Bianchi, M Rescigno
The EMBO journal 29 (13), 2242-2252, 2010
1922010
Adenosine 2B receptor expression on cancer cells promotes metastasis
D Mittal, D Sinha, D Barkauskas, A Young, M Kalimutho, K Stannard, ...
Cancer research 76 (15), 4372-4382, 2016
1572016
Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis
D Mittal, D Vijayan, EM Putz, AR Aguilera, KA Markey, J Straube, ...
Cancer immunology research 5 (12), 1098-1108, 2017
1192017
CD73 promotes resistance to HER2/ErbB2 antibody therapy
M Turcotte, D Allard, D Mittal, Y Bareche, L Buisseret, V José, S Pommey, ...
Cancer research 77 (20), 5652-5663, 2017
1022017
NK cells require IL-28R for optimal in vivo activity
F Souza-Fonseca-Guimaraes, A Young, D Mittal, L Martinet, C Bruedigam, ...
Proceedings of the National Academy of Sciences 112 (18), E2376-E2384, 2015
932015
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
D Mittal, A Lepletier, J Madore, AR Aguilera, K Stannard, SJ Blake, ...
Cancer immunology research 7 (4), 559-571, 2019
902019
Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer
PV Raninga, AC Lee, D Sinha, YY Shih, D Mittal, A Makhale, AL Bain, ...
International journal of cancer 146 (1), 123-136, 2020
692020
CEP 55 is a determinant of cell fate during perturbed mitosis in breast cancer
M Kalimutho, D Sinha, J Jeffery, K Nones, S Srihari, WC Fernando, ...
EMBO molecular medicine 10 (9), e8566, 2018
682018
Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov. 2014; 4: 879–888. doi: 10.1158/2159-8290
A Young, D Mittal, J Stagg, MJ Smyth
CD-14-0341.[Abstract][CrossRef][Google Scholar], 0
67
Indoleamine 2, 3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7
D Mittal, AJ Kassianos, LS Tran, AS Bergot, C Gosmann, J Hofmann, ...
Journal of Investigative Dermatology 133 (12), 2686-2694, 2013
592013
New approaches to immunotherapy for HPV associated cancers
AS Bergot, A Kassianos, IH Frazer, D Mittal
Cancers 3 (3), 3461-3495, 2011
592011
Intra‐tumoral Salmonella typhimurium induces a systemic anti‐tumor immune response that is directed by low‐dose radiation to treat distal disease
F Avogadri, D Mittal, F Saccheri, M Sarrafiore, M Ciocca, P Larghi, ...
European journal of immunology 38 (7), 1937-1947, 2008
522008
Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice
J Overman, F Fontaine, M Moustaqil, D Mittal, E Sierecki, N Sacilotto, ...
Elife 6, e21221, 2017
502017
CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity
A Roman Aguilera, VP Lutzky, D Mittal, XY Li, K Stannard, K Takeda, ...
Oncoimmunology 7 (5), e1424677, 2018
482018
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis
H Harjunpää, SJ Blake, E Ahern, S Allen, J Liu, J Yan, V Lutzky, K Takeda, ...
Oncoimmunology 7 (7), e1445949, 2018
452018
The system can't perform the operation now. Try again later.
Articles 1–20